Alendronate Sodium
Product Images NDC 53217-321

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 53217-321). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aidarex Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Arrow (Alendronate Sodium Usp 35mg Tablet 1)

The image shows a round, white tablet identified as alendronate sodium by Aidarex Pharmaceuticals LLC. There are markings on the tablet, including a score line and the imprint '54,' indicating dosage or identification details. The background is a plain, light surface highlighting the tablet clearly.*

FDA Label Image

Arrow (Alendronate Sodium Usp 35mg Tablet 10)

The image shows a rectangular white pharmaceutical carton for Alendronate Sodium by Aidarex Pharmaceuticals LLC, NDC 53217-321. The label includes the proprietary name 'alendronate sodium' prominently, with a simple blue and white color scheme and the Aidarex Pharmaceuticals LLC logo. Additional text details are small and not fully legible in the image.*

FDA Label Image

Alendronate Sodium, Usp Tablet (Alendronate Sodium Usp 35mg Tablet 11)

Packaging label for Alendronate Sodium USP 35MG oral tablets by Aidarex Pharmaceuticals LLC. The label shows a 4-count package with each tablet containing 45.68MG of Alendronate Sodium (35MG free acid equivalent). It is generic for Fosamax with NDC 53217-0321-01. The label includes lot number, manufacturer details, and warnings.*

FDA Label Image

Arrow (Alendronate Sodium Usp 35mg Tablet 2)

alendronate sodium 70 mg oral tablet blister pack by Aidarex Pharmaceuticals LLC, showing five tablets in a row within a transparent blister strip. The pack background is mainly green with white labeling.*

FDA Label Image

Structural Formula For Alendronate Sodium (Alendronate Sodium Usp 35mg Tablet 3)

Chemical structure of alendronate sodium depicting the molecular arrangement including amine and phosphate groups along with sodium and water of hydration components.*

FDA Label Image

Cumulative Incidence Of Hip Fractures In The Three-year Study Of Fit (patients With Radiographic Vertebral Fracture At Baseline) (Alendronate Sodium Usp 35mg Tablet 4)

A line graph showing cumulative incidence percentage over time in months for Alendronate Sodium versus placebo. The x-axis represents time in months from 0 to 36, and the y-axis represents cumulative incidence percentage from 0 to 10%. Two lines are plotted: a solid line for Alendronate Sodium and a dashed line for placebo, with the placebo line showing a higher cumulative incidence over time compared to Alendronate Sodium.*

FDA Label Image

Osteoporosis Treatment Studies In Postmenopausal Women Increase In Bmd Alendronate Sodium 10 mg/day At Three Years (Alendronate Sodium Usp 35mg Tablet 5)

A bar chart comparing the mean percentage increase in bone mineral density (BMD) relative to placebo, with standard error, at three anatomical sites: lumbar spine, femoral neck, and trochanter. Data are shown for two groups labeled U.S. and Multinational.*

FDA Label Image

Osteoporosis Treatment Studies In Postmenopausal Women Time Course Of Effect Of Alendronate Sodium 10 mg/day Versus Placebo: Lumbar Spine Bmd Percent Change From Baseline (Alendronate Sodium Usp 35mg Tablet 6)

Two line graphs comparing bone mineral density (BMD) percent change from baseline over 36 months in U.S. and multinational studies. Both show BMD increases with alendronate sodium 10 mg compared to placebo, presented with means and standard error. The x-axis is time in months; the y-axis is percent BMD change.*

FDA Label Image

Osteoporosis Prevention Studies In Postmenopausal Women (Alendronate Sodium Usp 35mg Tablet 7)

Two bar charts showing the change in bone mineral density (BMD) from baseline in a 2-year and a 3-year study comparing Alendronate Sodium 5mg/day to placebo. The charts display mean percentage change with standard error for lumbar spine, femoral neck, trochanter, and total body BMD.*

FDA Label Image

Studies In Glucocorticoid (Treated Patients Increase in BMD Alendronate Sodium 5 mg/day at One Year)

A bar chart comparing the mean percentage increase in bone mineral density (BMD) relative to placebo at the lumbar spine, femoral neck, and trochanter. Two groups are represented: U.S. subjects (striped bars) and Multinational subjects (solid bars), with error bars indicating standard error (SE).*

FDA Label Image

Studies In Paget’s Disease Of Bone Effect On Serum Alkaline Phosphatase Of Alendronate Sodium 40 mg/day Versus Placebo Or Etidronate 400 mg/day (Alendronate Sodium Usp 35mg Tablet 9)

A line graph displaying the percent change from baseline in serum alkaline phosphatase over 6 months. It compares four groups: placebo, etidronate 400 mg/day, alendronate sodium 40 mg/day multinational study, and alendronate sodium 40 mg/day U.S. study, showing changes at baseline, 3 months, and 6 months with sample sizes noted for each group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.